Biogen's debated Alzheimer's drug given to first patient
Fox News
A Rhode Island man became the first patient worldwide to receive Biogen’s hotly debated Alzheimer’s drug outside of a clinical trial on Wednesday, a hospital spokesperson confirmed to Fox News.
"It’s transforming how we treat Alzheimer’s," Dr. Stephen Salloway, director of the memory and aging program at Butler Hospital, said at a press conference. "For those of you who don’t know, it’s a devastating disease." "Marc actually tried out for aducanumab [trials] twice but he flunked because he did too well on his memory tests," Salloway said. "We knew he had Alzheimer’s and he was building up amyloid plaques in the brain and had an increased genetic risk for Alzheimer’s."More Related News
University president retires after being reprimanded for caving to demands of anti-Israel protesters
Sonoma State University President Mike Lee announced his retirement this week after being placed on administrative leave for making unauthorized concession to anti-Israel students.